MMP-9 and/or TIMP as predictors of ischaemic stroke in patients with symptomatic and asymptomatic atherosclerotic stenosis of carotid artery treated by stenting or endarterectomy – A review by Zielinska-Turek, Justyna et al.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 5 5 – 5 6 1
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnnsReview articleMMP-9 and/or TIMP as predictors of ischaemic
stroke in patients with symptomatic and
asymptomatic atherosclerotic stenosis of carotid
artery treated by stenting or endarterectomy – A
reviewJustyna [2_TD$DIFF]Zielinska-Turek a,*, Małgorzata Dorobek a, Grzegorz Turek b,
Maria Barcikowska-Kotowicz c
aDepartment of Neurology, Central Clinical Hospital of Ministry of the Interior and Administration, Warsaw, Poland
bDepartment of Neurosurgery, Bródno Mazovia Hospital, Warsaw, Poland
c Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Mossakowski Medical Research Center,
Polish Academy of Sciences, Warsaw, Polanda r t i c l e i n f o
Article history:
Received 11 March 2018
Accepted 23 May 2018
Available online 30 May 2018
Keywords:
Stroke
MMP-9
TIMP
Carotid stenosis
[1_TD$DIFF]Endarterectomy
a b s t r a c t
We still lack an optimal tool to predict ischaemic stroke in patients with symptomatic and
asymptomatic carotid stenosis (CS). It has already been shown that patients at increased risk
of ischaemic stroke can be identiﬁed based on the elevated plasma levels of metalloprotei-
nases (MMPs) and reduced activity tissue inhibitor ofmetalloproteinase (TIMP). There are few
studies presenting the role of MMP-9 and TIMP in ischaemic stroke both in patients with
symptomatic and asymptomatic CS treated with stenting or endarterectomy, however we
have not found any published review summarizing the role of abovementioned markers.
MEDLINEwas accessed via PubMed, and searched for published studies that analyzedMMP-9
and TIMP levels in patients with asymptomatic and symptomatic internal carotid stenosis
and/or examined theseparameters aspotential riskmarkers for ischaemic stroke.A total of 13
articles documenting the outcomes of patients with symptomatic or asymptomatic carotid
stenosis treated by carotid stenting or endarterectomy,were analyzed. Statistically signiﬁcant
differences in the levels of MMP-9 and/or TIMP in patients with symptomatic and asymp-
tomatic CS have been reported. Also the concentrations of MMP-9 and TIMP in CS patients
subjected to stenting or endarterectomywere higher than in baseline group. Moreover higher
levels of MMP-9 and decreased TIMPwas reported to be associatedwith the risk of restenosis.
This systematic review shows that available evidence regarding the dynamics of MMP-9 and
TIMP levels may be a predictor of cerebrovascular events in both symptomatic and asymp-
tomatic carotid stenosis in patients treated with stenting or endarterectomy.
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permanent disability in adults [1,2]. Atherosclerotic disease of
the internal carotid artery results in carotid stenosis (CS), an
established cause of ischaemic stroke. The prevalence of
hemodynamically relevant CS (≥50%) in subjects >65 years of
age is quite high (5–10%) [3,4]. According to literature,
asymptomatic CS (50–99%) contributes substantially to 1–
3.4% annual stroke rate [5]. Since both CS and modiﬁable risk
factors for ischaemic stroke have been studied quite exten-
sively, an obvious direction of further research was to identify
the subjects at increased risk of stroke to provide them with
adequate preventive measures. Interestingly, however, both
the U.S. Preventive Service Task Force (USPSTF) and the AHA
Primary Prevention of Stroke guidelines do not recommend
screening for CS in general adult population [6]. This policy has
been explained by difﬁculties in the identiﬁcation of patients
who may beneﬁt from endarterectomy/stenting or pharmaco-
therapy alone. The validity of this assumption has been also
conﬁrmed by the results of the largest two trials that had been
conducted thus far: Asymptomatic Carotid Atherosclerosis
Study (ACAS) and Asymptomatic Carotid Artery Trial (ACAT).
None of these studies demonstrated a link between the
severity of CS and the risk of stroke in asymptomatic patients.
Moreover, published evidence suggests that currently avail-
able diagnostic procedures: duplex ultrasound and computed
tomography could not adequately assess the risk of stroke in
asymptomatic CS.
The review of the abovementioned recommendations shows
clearly that we lack an optimal strategy to predict ischaemic
stroke in patients with asymptomatic CS. However, some
previous studies demonstrated that matrix metalloproteinases
may play a role in vascular remodelling and destabilization of
atherosclerotic plaques in the internal carotid arteries [7].
Furthermore, it has already been shown that patients at
increased risk of ischaemic stroke can be identiﬁed based on
the elevated plasma level of MMPs and reduced activity tissue
inhibitor of metalloproteinase (TIMP), i.e. characteristic features
of atherosclerotic plaque instability. This is a relatively recent
ﬁnding; therefore the issuewas the subject of only fewpublished
studies. Nevertheless, analysis of plasma MMP and TIMP levels
seems to be highly promising in the context of stroke prediction
in asymptomatic patients with CS.
However, we did not ﬁnd any published review paper
summarizing recent studies examining the role of MMP-9 and
TIMP levels in patients subjected to carotid stenting or
endarterectomy due to asymptomatic or symptomatic CS.
Therefore, the aim of this systematic review was to present
available evidence regarding the dynamics of MMP-9 and TIMP
levels as a predictor of cerebrovascular events in CS.2. Clinical implications
2.1. Search strategy
MEDLINE was accessed via Pub Med, and searched for
published studies that analyzed MMP-9 and TIMP levels inpatientswith asymptomatic and symptomatic internal carotid
stenosis and/or examined these parameters as potential risk
markers for ischaemic stroke. The searchwas based on various
combinations of the following keywords and phrases: 'ischae-
mic stroke', 'internal carotid artery stenosis', 'MMP-9', 'TIMP',
'atherosclerosis', 'cardiovascular disease' and 'metalloprotei-
nase'. Also PubMed's 'related articles' functionality was used
to identify publications that have not been found by means of
the keyword search.
2.2. Inclusion/exclusion criteria
The review included MEDLINE-indexed papers published
between 1989 and 2017, and non-indexed articles of Polish
authors. The studies of patients under 18 years of age, animal
models, cadaveric experiments, letters to the editors were not
eligible for the review. Also the papers that did not provide any
information about MMP-9 and TIMP levels, and those
presenting concentrations of these markers solely in athero-
sclerotic plaques were excluded from the analysis.
2.3. Data extraction
Two independent authors (J.Z.-T. and M.D.) extracted the
following data from the eligible publications: (1) type of the
study, (2) characteristics of the study group, (3) MMP-9 and
TIMP levels in the study subjects, and (4) relationship between
concentrations of these markers and the study outcome, if
any. Characteristics of the study type included information
whether the results were collected prospectively or retrospec-
tively, also about follow-up duration, inclusion/exclusion
criteria and outcome measures. Characteristics of the study
group included the number of patients, theirmean age, clinical
status at hospital admission and CS severity. MMP-9 and TIMP
levels were recorded for patients with asymptomatic and
symptomatic internal carotid artery stenosis, as well as for
individuals who underwent carotid stenting (CAS) and carotid
endarterectomy (CEA).
A total of 13 articles, all written in English, documenting the
outcomes of 1097 patients with symptomatic (SCS) or
asymptomatic carotid stenosis (ACS) treated by either carotid
stenting or endarterectomy, were analyzed. The largest group
consisted of 300 patients, the smallest of 11 patients.
Clinical characteristics of SCS and ACS patients included in
these studies are summarized in Table 1, separately for
individuals subjected to carotid stenting (CAS) and for those
treated by carotid endarterectomy (CEA). MMP-9 and TIMP
levels in those groups are shown in Table 2.
2.4. MMP-9 and TIMP levels in patients with symptomatic
and asymptomatic carotid stenosis
Statistically signiﬁcant differences in MMP-9 and/or TIMP
levels in patients with symptomatic (e.g. ischaemic stroke,
transient ischaemic attack – TIA, amaurosis fugax – AF) were
demonstrated in two papers and asymptomatic CS in only one
(Table 2). The authors of a Polish study found no signiﬁcant
differences in baseline plasma levels ofMMP-9 of patientswith
symptomatic and asymptomatic CS (0.14 ng/L, range 0.1–
Table 1 – Description of studies.
Reference Year Participants Assay Outcomes/aim Conclusion
Loftus et al.
[11]
2000 Patient with
asymptomatic and
symptomatic CS admitted
for carotid
endarterectomy (CEA)
UK: 75 patients ELISA (24 h
preoperatively)
Proﬁle of MMPs
(1, 2, 3 and 9),
TIMPs (1, 2)
 Expression of MMP-9 is
signiﬁcantly higher in
symptomatic patients only 1
month before CEA, moreover in
unstable carotid plaques.
 MMP-9 may be a strong
candidate for pharmacotherapy
aimed at stabilizing plaques and
preventing stroke
Alvarez
et al. [10]
2004 Patients with
symptomatic (stroke, TIA,
ASX) and symptomatic CS
classiﬁed for TEA
Spain: 40
patients (27 S,
13 AS)
ELISA (24 h before
surgery)
Proﬁle of MMPs
(2, 9)
 MMP-9 was signiﬁcantly
higher in the symptomatic
group and in patients with
unstable plaques
 MMP-2 was signiﬁcantly
higher in patients with
symptoms
Eldrup et al.
[9]
2006 Patient referred for carotid
ultrasound examination,
symptomatic or
asymptomatic
Denmark: 207
patients (88 AS,
119 S)
ELISA (after the
ultrasound
examination)
Proﬁle of MMP-9  MMP-9 level associated with 2
fold risk of stroke or CVD
Gondalia
et al. [18]
2007 Patients with
symptomatic (stroke, TIA,
ASX) CS classiﬁed for CEA
Sweden: 13 (all
symptomatic)
ELISA (1, 5, 9 min
before clamping, just
before clamping and
15 min after start of
reperfusion)
Proﬁle of MMP-9,
MCP-1, ICAM-1
and oxLDL
 No statistically signiﬁcant
change was observed
concerning MMP-9 during
surgery
Suzue et al.
[13]
2007 Patients with
symptomatic (stroke) and
asymptomatic CS
classiﬁed for CEA
Japan: 112
patients (72 S,
40 AS)
 ELISA (during
surgery)
Zymography (carotid
plaques)
Proﬁle of MMPs
(2, 9)
 There was no signiﬁcant
difference with respect to the
activity MMP-9, although it was
greater in the vulnerable than
stable plaques
Taurino
et al. [20]
2008 Patients with
symptomatic and
asymptomatic CS
admitted for TEA
Italy: 15
patients
ELISA (before surgical
procedure, 1 week and
1 month thereafter)
Proﬁle of MMPs
(2, 9) and TIMP-2
 MMP-9 before surgery was
signiﬁcantly higher in patients
with CS than in healthy control
 MMP-9 at week after surgery
was decreased, and 1 month
drastically decreased
 MMP-2 was higher in patients
with CS than controls
 TIMP-2 no signiﬁcant changes
in baseline, 1 week and 1 month
after surgery, and in control
group
Setacci
et al. [17]
2008 Patients with
symptomatic (stroke, TIA,
ASX) and asymptomatic
CS classiﬁed for CAS
Italy: 57
patients
ELISA (before stenting,
immediately
afterwards and at the
30 day follow-up)
Proﬁle of MMPs
(2, 9), PAPP-A,
hs-CR, IL-6
 No statistically signiﬁcant
change was observed in levels
MMP-9 and MMP-2
Ishigaki
et al. [19]
2008 Patients with
symptomatic (stroke, TIA)
and asymptomatic CS
undergoing CEA for
ipsilateral internal ICA
Japan: 41
patients (21 S,
20 AS)
ELISA (5 min after
intravenous
administration of
heparin and
immediately before
clamping of the ICA, 1,
5 and 20 min after
declamping ICA)
Proﬁle of MMP-9  The concentrations of MMP-9
at 20 min after ICA declamping
were signiﬁcantly higher than
those before ICA clamping or at
1 min after ICA declamping
Sapienza
et al. [21]
2009 Patient with symptomatic
and asymptomatic,
severe, recurrent carotid
artery stenosis
Italy: 52
patients
ELISA Proﬁle of MMPs
(2, 9) and TIMPs
(1, 2)
 Patients with symptomatic
restenosis had signiﬁcantly
higher active MMP-2 and 9,
lower TIMP-1 and 2
Musialek
et al. [8]
2013 Patient with CS ≥50%
symptomatic or
asymptomatic
Poland: 300
patients (110
AS, 190 S)
ELISA (morning
between 7 and 9 a.m.
at admission)
Proﬁle of MMPs
(8,9,10), TIMP, IL
(1b, 6, 8,18),
leptin
 Plasma levels of the MMPs did
not differ between the study
group
 TIMP was signiﬁcantly lower in
the CS-symptomatic patients
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Reference Year Participants Assay Outcomes/aim Conclusion
Zhang et al.
[16]
2015 Patients with
symptomatic (stroke) and
asymptomatic CS
classiﬁed for CAS
China: 74
patients (43 S,
31 AS)
ELISA (before stenting,
at 24 h, 3 and 6
months after CAS
procedure)
Proﬁle of MMP-9,
IL-1b, IL-6, TGF-
b, MCP-1 and
sVCAM-1
 MMP-9 increased 24 h after
stenting
 MMP-9 – high expression
continued for at last 3 months
after stent implantation
Gabrile
et al. [12]
2016 Patients with
symptomatic (stroke, TIA,
AF) and asymptomatic CS
classiﬁed for CEA
Brazil: 11
patients (6 S, 5
AS)
ELISA (preoperative
period and 1, 6 and
24 h after CEA)
Proﬁle of MMPs
(8, 9), IL (1b, 4, 6,
8, 10), TNF-a, hs-
CRP, VEGF
 Peak serum values for MMP-8,
MMP-9, IL-6 and IL-10 were
observed 6 h after CEA
 Symptomatic patients
exhibited higher serum
concentrations of MMP-8, MMP-
9, IL-1b, IL-4, IL-8, hs-CRP, TNF-a
Lekic et al.
[14]
2017 Patients with
symptomatic and
asymptomatic CS
Croatia: 100
patients (40
with mild
artherosclerosis of
carotid artery disease,
40 with
artherosclerosis of
carotid artery disease,
20 healthy volunteers
ELISA Proﬁle of MMPs (2, 9) in urine,
and CD4, CD25 and Foxp3 in
blood
 Signiﬁcant increase
MMP-2 in patients with
large stenosis of the
carotid artery
 Statistically signiﬁcant
difference in the MMP-9
enzyme concentration in
patients with
artherosclerosis, stenosis
and the controlled group
S, symptomatic; AS, asymptomatic; CEA, carotid endarterectomy; CVD, cardiovascular death; TEA, thromboendarterectomy; TIA, transient
ischaemic attack; AF, amaurosis fugax; MMP, matrix metalloproteinase; MMPs, matrix metalloproteinases; TIMP, tissue inhibitor of
metalloproteinases; TIMPs, tissue inhibitors of metalloproteinases; CAS, carotid artery stenting; ICA, internal carotid artery.
Table 2 – MMP-9 and TIMP levels in patients with symptomatic and asymptomatic carotid stenosis (CS).
References Symptomatic CS (SCS) Asymptomatic CS (ACS) MMP-9 SCS vs ACS TIMP SCS vs ACS
MMP-9 TIMP MMP-9 TIMP
Musialek et al. [1] 0.14 ng/L 130.7 ng/ml 0.13 ng/L 146.2 ng/L Not signiﬁcant Signiﬁcant
Alvarez et al. [3] 1026.1 ng/ml N/A 377.84 ng/ml N/A Signiﬁcant N/A
Eldrup et al. [2] 47 N/A 40 N/A Signiﬁcant N/A
N/A, not applicable.
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patients showed no statistically signiﬁcant differences in
MMP-9 levels determined prior to and 6 months after the
manifestation of the last symptoms. However, symptomatic
and asymptomatic patients participating in this study differed
signiﬁcantly in terms of their TIMP levels (130.7 ng/ml vs.
146.2 ng/ml). Eldrup et al. analyzedMMP-9 levels in CS patients
with ipsilateral stroke/cardiovascular death and in subjects
with asymptomatic CS contrary to Musialek found statistically
signiﬁcant intergroupdifferences inMMP-9 levels (47 ng/ml vs.
40 ng/ml) [9]. They also demonstrated that the probability of
ipsilateral stroke or cardiovascular death in patients in whom
plasma concentration of MMP-9 exceeded the median value
for the study group (41.9 ng/mL) was signiﬁcantly higher than
in those with lower (what was the cut off) blood levels of this
metalloproteinase. Also Alvarez et al. found a statisticallysigniﬁcant association between an increase in serum concen-
tration of MMP-9 and presence of symptomatic CS [10]. In the
study conducted by these authors, mean concentrations of
MMP-9 in symptomatic and asymptomatic CS patients
amounted to 1026.10  412.9 ng/mL and 377.84  164.08 ng/
mL, respectively. Loftus et al. presented signiﬁcantly higher
concentration of MMP-9 in symptomatic patients with CS, but
only within one month before CEA. There was no differences
in asymptomatic patients, symptomatic >6 months and 1–6
months before surgery [11]. Also Gabrile et al. showed similar
ﬁndings, however not only MMP-9 serum concentration in his
group was higher in symptomatic patients, but also of MMP-8,
IL-1b, IL-4, IL-8, hs-CRP, TNF-a [12]. Interestingly, both Loftus
et al. and Suzue et al. showed that the concentration,
production, and expression of MMP-9 was signiﬁcantly higher
in unstable carotid plaques [11,13]. Other papers were
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paper, the authors showed statistically signiﬁcant increase in
levels of MMP-9 in urine of patients with higher degree of
stenosis and symptomatic plaque – average values for stenosis
<60% vs 79–99% amounted to 3679.5 pg/ml vs. 859.7 pg/ml,
respectively [14]. In the second paper the authors showed that
circulating MMP-9/NGAL complex is associated with athero-
sclerotic plaque vulnerability in patients with carotid artery
stenosis [15].
2.5. Concentrations of MMP-9 and/or TIMP in CS patients
subjected to stenting (CAS) or endarterectomy (CEA)
Zhang et al. conducted an extensive study to verify an
association between serum level of MMP-9 and the stenting
procedure. In this study, concentrations of MMP-9 were
assessed prior to the procedure, 24 h, 3- and 6-month
thereafter [16]. Elevated levels of MMP-9 were observed for
at least 3 months post-procedure, which suggested that this
metalloproteinase may be involved in the process of in-stent
stenosis. Aside from a tendency to intra-procedural bleeding,
carotid stenting was not associated with any other complica-
tions. Analyse of MMP-9 level in patientswith symptomatic CS
treated by stenting (n = 57) showed elevated levels of MMP-9
not only 24 h post-stenting but also up to 30 days thereafter;
concentrations ofMMP-9 determinedprior to the stenting, 24 h
and 30 days post-procedure amounted to 100 pg/ml, 125 pg/ml
and 118 pg/ml, respectively (Setacci et al. similar to Zhang
et al.). Carotid stenting was associated with two TIA episodes
directly after the procedure, two TIA episode and death within
a month after the discharge from the hospital [16,17].
Contrary to thementioned above reports, which focused on
a link between carotid stenting and MMP-9 levels in CS
patients, Gondalia et al. analyzed an association between
serum concentration of this metalloproteinase and endarter-
ectomy [18]. Serum levels of MMP-9were analyzed prior to and
during clamping of the artery, and 15 min after its release.
Althoughmean levels of MMP-9 during and after the clamping
were higher than at the baseline, the difference in the whole
study group was not statistically signiﬁcant. However, a
signiﬁcant increase in MMP-9 level was found in patients
with diabetes mellitus, high concentrations of haemoglobin,
high leucocyte and platelet counts, as well as in individuals
with contralateral stenosis, whereas older persons, subjects
with elevated blood pressure and those operated on for the
left-side stenosis presented with signiﬁcantly lower concen-
trations of this metalloproteinase. Similar results were
reported by Ishigaki et al. [19]. In this study serum concentra-
tions of MMP-9 at 1, 5 and 20 min after the ICA declamping
were signiﬁcantly higher than at the baseline ( p < 0.05).
Interestingly, 3 out of 41 participants of this study, who
recovered from anaesthesia with new neurologic deﬁcits,
presentedwith thehighest concentrations ofMMP-9 at 1, 5 and
20 min post-declamping. In another study, Taurino et al.
analyzed concentrations of MMP-9 and TIMP prior to CEA, as
well as 1week and 1month after the procedure;moreover, this
study included a control group [20]. Baseline concentration of
MMP-9 in patients qualiﬁed for CEA (23.8 ng/mL) turned out to
be signiﬁcantly higher than in healthy controls (11.4 ng/mL).
Althoughpatientswith symptomatic CSpresentedwith higherbaseline plasma levels of MMP-9 than individuals with the
asymptomatic stenosis, the difference was not statistically
signiﬁcant. However, baseline plasma concentrations of MMP-
9 in persons with an evidence of cerebral lesions on
preoperative neuroimaging were signiﬁcantly higher than in
the controls. One week and one month after the CEA, a
decrease in MMP-9 level was observed in nearly 50% and in
more than 90% of the study subjects, respectively. Contrary to
MMP-9, no statistically signiﬁcant changes were observed in
plasma levels of TIMP in CS patients and controls, either at the
baseline or after a 1-week/1-month follow-up.
2.6. Association between MMP-9 and TIMP levels and the
risk of restenosis
One published study analyzed an association between
elevated levels of MMP-9 and TIMP and the risk of restenosis
after CEA. The study conducted by Sapienza et al. included 621
patients subjected to CEA, among them 52 patients with
symptomatic and asymptomatic internal carotid artery reste-
nosis [21]. The restenosis was classiﬁed as early, intermediate
and late. Individuals with restenosis, either active or latent
one, presented with elevated levels of MMP-9 and decreased
concentrations of TIMP. Detailed analysis demonstrated lower
levels of TIMP in symptomatic patients as well as individuals
with late restenosis.
3. Future directionsWe have reviewed 13 recent publications documenting
applicability of MMP-9 and TIMP as predictors of cerebrovas-
cular event in patients with asymptomatic or symptomatic CS
treated by stenting or endarterectomy. Available evidence is
limited to formulate any unequivocal conclusions in this
matter. Most previous studies demonstrated that after stent-
ing or endarterectomy, patients with symptomatic CS showed
an increase in MMP-9 concentration and a decrease in TIMP
level. Therefore, most researchers concluded that both MMP-9
and TIMP may serve as markers of brain ischaemia in CS
patients [9,10].
The study conducted by Eldrup et al. adds to this evidence,
showing that patients with MMP-9 concentrations exceeding
medianvalue for thewhole studygroup (41.9 ng/ml) had twice as
high the risk of ipsilateral stroke than the remaining subjects.
The study demonstrated that patients with symptomatic CS
presented with elevated levels of MMP-9, which the authors
speculated to result from an increase in the number of cells
releasing this enzyme, i.e. macrophages and leukocytes. This
hypothesis was also conﬁrmed by Loftus et al. [11] who found
that the level of MMP-9 within the atherosclerotic plaques of
patients with a recent history of CS symptoms was signiﬁcantly
higher than in individuals who did not experience any
symptoms for more than one month. According to Alvarez et
el., metalloproteinases may be responsible for destabilization of
atherosclerotic plaques, and may play an important role in the
etiopathogenesis of cerebral ischaemic events. These authors
found elevated levels of MMP-9 both in patients with a history of
ischaemic events and in patients with unstable atherosclerotic
plaques, and observed a positive correlation between concen-
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within the plaques. These ﬁndings were conﬁrmed by other
authorswho demonstrated a link between an increase inMMP-9
level, plaque instability and resultant greater likelihood of a
cerebral ischaemic event [22–25]. According to Alvarez et al.,
these ﬁndings may have diagnostic and therapeutic implica-
tions, since elevated plasma level of MMP-9 may be useful in
identiﬁcation of patients at increased risk of stroke. However,
Musialek et al. concluded that circulating biomarkers, such as
MMP-9 and TIMP, are not accurate predictors of symptomatic CS
[8]. In the study conducted by these authors, patients with
symptomatic CS showed a decrease in TIMP levels, which
suggested a disruption in MMP-9/TIMP balance, but without a
concomitant change in MMP-9 level.
In all previous studies, CS patients who had been subjected
to carotid stenting or endarterectomy showed an increase in
MMP-9 levels [12,13]. According to Zhang et al., elevated levels
of this metalloproteinase was present immediately after the
CAS, and also after a longer follow-up period. This implies that
metalloproteinasesmay also play an important role in in-stent
restenosis, which has been already conﬁrmed in a CS patient
after stenting [26]. Using a new in vitro model, the authors
demonstrated that the expression of MMP-9 may be regulated
by suppression of ERK1/2/Elk-1 pathway (extracellular signal –
regulated kinases1/2/humans encoded by theELK1gene).
Moreover, they showed that administration of telmisartan,
an established suppressor of ERK 1/2, may reduce morbidity
after CAS. Setacci et al. conﬁrmed that CAS is a safe procedure
in patients with symptomatic CS treated shortly after the
onset of symptoms. They showed that CASdoes not pose a risk
of neurological complications, yields high success rate and it
associated with very low postoperative incidence of minor
cerebrovascular events. Aside fromMMP-9, the authors of this
study also determined serum levels of other markers, such as
PAPP-A, Hs-CRP, IL-6, etc. Although the study showed an
increase in serum concentration of MMP-9 that persisted for
up to 30 days after CAS, the authors concluded that in contrast
to PAPP-A, Hs-CRP and IL-6, this metalloproteinase is not an
accurate marker of atherosclerotic plaque destabilization in
patients subjected to CAS due to symptomatic CS. All three
studies analysing MMP levels in CS patients treated by
endarterectomy demonstrated a post-procedure increase in
this marker. Interestingly, the authors of one of those studies,
Gondalia et al., found a positive correlation between the levels
of free radicals and MMP-9, which implies that this metallo-
proteinase may play a role in the pathophysiology of brain
tissue damage. Aside from the level of free radicals, concen-
tration of MMP-9 correlated also positively with the number of
leukocytes (a source of metalloproteinases), presence of
concomitant diabetes mellitus or contralateral stenosis. More
advanced atherosclerosis is known to be associated with
elevatedmetalloproteinase level) [27,28]. Similar ﬁndingswere
also reported by Ishigaki et al. who observed elevated levels of
MMP-9 in the jugular bulb not only after the artery clamping,
but also for at least 20 min after declamping. Moreover, they
demonstrated that patients with transient post-procedure
neurological deﬁcits presented with signiﬁcantly higher MMP-
9 levels than healthy controls. This implies thatMMP-9may be
an accurate marker of cerebral insult resulting from hypo-
perfusion during CEA. Furthermore, the authors emphasizedthat the increase in MMP-9 level in patients after CEA may
result also from scalp ischaemia during clamping of the
external carotid artery, even if blood was collected just above
the conﬂuence of the common facial vein [19,20].
A few recent studies addressed the problem of in-stent re-
stenosis in patients after CAS [21]. However, the results of this
research are inconclusive and it is still unclear if MMP-9 may be
considered a marker of coronary restenosis. The only study
analysing the issue in relation to carotid arteries has been
conducted by Sapienza et al. According to these authors, an
increase in MMP-9 level was the only independent predictor of
in-stent restenosis in the carotid artery [20]. Importantly,
concentrations of MMP during the late phase of in-sent
restenosis were signiﬁcantly higher than at earlier stages of
the process. In-stent restenosis was associated with a decrease
in TIMP levels. The authors speculated that the changes inMMP-
9 and TIMP levels were associated with the release of growth
factors and cytokines within the atherosclerotic plaques. They
concluded that patients who require repeated intervention due
to increased riskof in-stent restenosismaybe identiﬁedbasedon
the dynamics of their plasma MMP-9/TIMP levels.
Recently the discussion concerning relation betweenMMPs
and inﬂammatory/immunological process within atheroscle-
rotic plaque has been raised in publications. Eilenberg et al.
observed that patients with atherosclerotic changes have
signiﬁcantly lower percentage of T lymphocytes in peripheral
blood compared to the healthy volunteers. The authors found
correlations between regulatory immune process and the level
of MMP – downregulation of the enzymes level of MMP-9 and
percentage of regulatory T cells [15]. Ammirati also stated that
inﬂammatory/immune proﬁle of the patients may play
important role in the assessment of the risk of stroke
[14,29]. Cytokines such as IL-6 and THFa are useful in
prediction of plaque presence, whereas metalloproteins may
be useful in prediction of its instability.
One potential limitation of this study may be a publication
bias resulting from preferential publishing of the studies that
documented the accuracy of MMP-9/TIMP as biomarkers.
Furthermore, it should be remembered that the levels of
MMP-9 documented by various authors might be also inﬂu-
enced by centre-speciﬁc differences in CAS and CEA techni-
ques. There is still not enough evidence to conclude
unequivocally that an increase in MMP-9 concentration and
a concomitant decrease in TIMP level could become accurate
markers of ongoing ischaemia. The systematic review of
limited published data suggests that concentration of MMP-9
may reﬂect changes in brain circulation, such as hypoperfu-
sion. However, still more evidence is needed to support the
notion that MMP-9/TIMP are independent predictors of
cerebrovascular events in patients with CS.
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